DBAF 301Alternative Names: DBAF-301
Latest Information Update: 29 Jul 2016
At a glance
- Originator ioGenetics
- Class Antibacterials; Antibodies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Community-acquired pneumonia
Most Recent Events
- 29 Jul 2016 Early research in Community-acquired pneumonia in USA (unspecified route)